Olema Pharmaceuticals (OLMA) Stock
Small cap biotech company developing novel medicines. Here's the price, business snapshot, and what's worth knowing about Olema Pharmaceuticals in October 2026.
Olema Pharmaceuticals Inc (ticker: OLMA) is a small-cap biopharmaceutical company (market cap about $568.3m) focused on developing and commercialising novel therapeutics. For investors, key considerations include the company’s development pipeline, clinical-trial milestones and regulatory progress — events that can cause significant share-price swings. Smaller biotech firms often have limited revenues and may rely on partnerships, licensing deals or capital raises to fund R&D. That creates upside potential if trials succeed but also heightens risk if results disappoint or financing terms are unfavourable. Liquidity can be lower than for larger stocks, which can increase volatility. Investors should review recent company filings, understand the stage and size of the pipeline, and factor in broader sector dynamics and regulatory trends. This summary is for educational purposes only and not personalised investment advice; seek professional guidance to assess whether OLMA fits your objectives and risk tolerance.
Olema Pharmaceuticals (OLMA) Stock Forecast
Analyst price target, next 12 months
$31.76
+286.2% vs today's $8.23
Price range over the last 12 months
Close to its 12-month low
Analysts covering Olema Pharmaceuticals have a consensus 12-month target of $31.76, above the current price of $8.23.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying OLEMA Pharmaceuticals' stock, predicting its value could rise significantly.
Financial Health
OLEMA PHARMACEUTICALS INC is showing strong cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Milestones
Clinical-trial readouts and regulatory steps can materially move the stock, though outcomes are uncertain and can increase volatility.
Financing & Partnerships
Funding rounds and licensing deals often shape the company’s runway and valuation, but may dilute shareholders or change strategy.
Sector Dynamics
Regulatory trends and competitive landscape in pharmaceuticals influence prospects; broader market sentiment also affects smaller-cap stocks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
